通化東寶(600867.SH)半年度扣非淨利潤預降4.96%
格隆匯7月14日丨通化東寶(600867.SH)公佈,預計2022年半年度實現歸屬於上市公司股東的淨利潤為136393.77萬元,與上年同期相比將增加69009.09萬元,同比增加約102.41%。
預計歸屬於上市公司股東的扣除非經常性損益的淨利潤為62296.72萬元,與上年同期相比將減少3249.78萬元,同比減少約4.96%。
本期業績變動的主要原因:1.公司根據經營發展需要,為集中力量加速向創新型藥企轉型,為企業中長期發展奠定堅實基礎,以及維護上市公司全體股東利益,出售廈門特寶生物工程股份有限公司部分股份,投資收益增加,使公司淨利潤增加。
2.報吿期內,胰島素國家專項集採落地,胰島素產品價格下降,而同時原材料價格上漲,導致報吿期內毛利率較去年同期下降;此外,部分地區受疫情影響,銷售收入不達預期,集採落地疊加疫情影響,導致扣除非經常性損益的淨利潤同比相應減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.